<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The consistent presence of the EBV genome in certain <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> offers the potential for novel EBV-directed therapies </plain></SENT>
<SENT sid="1" pm="."><plain>Switching the latent form of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> present in most EBV-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells into the cytolytic form may be clinically useful because lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> leads to host cell destruction, and very few <z:mpath ids='MPATH_458'>normal</z:mpath> cells contain the EBV genome </plain></SENT>
<SENT sid="2" pm="."><plain>It would also be therapeutically advantageous to induce expression of EBV-encoded lytic proteins that convert the <z:chebi fb="0" ids="33838">nucleoside</z:chebi> analogues <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> (GCV) and <z:chebi fb="0" ids="10110">3'-azido-3'deoxythymidine</z:chebi> (<z:chebi fb="39" ids="10110">AZT</z:chebi>) into their active, cytotoxic forms </plain></SENT>
<SENT sid="3" pm="."><plain>In this report, we have explored two different approaches for activating the lytic form of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We show that gamma-irradiation at clinically relevant doses induces lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> in lymphoblastoid cell lines in vitro as well as in EBV-positive B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in <z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:chebi fb="0" ids="17968">butyrate</z:chebi> (given as a single i.p </plain></SENT>
<SENT sid="6" pm="."><plain>dose) is effective for activating lytic <z:mp ids='MP_0001799'>viral</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in some EBV <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types in <z:mp ids='MP_0002536'>SCID</z:mp> mice </plain></SENT>
<SENT sid="7" pm="."><plain>We also examined whether low-dose gamma-irradiation treatment of EBV-positive lymphoblastoid cells in vitro promotes GCV or <z:chebi fb="39" ids="10110">AZT</z:chebi> susceptibility </plain></SENT>
<SENT sid="8" pm="."><plain>The combination of radiation with either GCV or <z:chebi fb="39" ids="10110">AZT</z:chebi> induced significantly more cell killing in vitro than either radiation or <z:chebi fb="0" ids="50266">prodrug</z:chebi> treatment alone </plain></SENT>
<SENT sid="9" pm="."><plain>Most importantly, we found that the combination of gamma-irradiation and GCV was much more effective in treating EBV-positive lymphoblastoid <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> in <z:mp ids='MP_0002536'>SCID</z:mp> mice than either agent alone </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, GCV or <z:chebi fb="39" ids="10110">AZT</z:chebi> treatment could potentially enhance the therapeutic efficacy of radiation therapy for EBV-positive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in patients </plain></SENT>
</text></document>